10010332  AMP-Deoxynojirimycin

Adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl)-Deoxynojirimycin; AMP-dNM (CAS 216758-20-2)



• See below for pricing and ordering
• See more Ceramides/Sphingolipids; Inhibitors; Diabetes; Inflammation

For active pharmaceutical ingredients (APIs) related to AMP-Deoxynojirimycin, see Cayman Pharma

The lipid messenger ceramide is converted to glucosylceramide by glucosylceramide synthase (GCS). In the reverse direction, non-lysosomal glucosylceramidase (GCase), also known as β-glucosidase 2 (BGD),1 cleaves the glucosyl moiety from glucosylceramide, liberating ceramide, which can be converted into sphingomyelin.2 AMP-deoxynojirimycin (AMP-dNM) is a hydrophobic derivative of dNM. It potently inhibits BGD (IC50 = 0.3 nM),3 less potently antagonizes GCS (IC50 = 25 nM),2 but only poorly inhibits other GCase isoforms. AMP-dNM has been shown to strongly suppress inflammation in a murine model of hapten-induced colitis,4 enhance insulin sensitivity in murine and rat models of insulin resistance,5 and induce sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in Hep-G2 cells.1
1  Bijl, N., Scheij, S., Houten, S., et al. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. J Pharmacol Exp Ther 326(3) 849-855 (2008).
2  Aerts, J.M., Hollak, C., Boot, R., et al. Biochemistry of glycosphingolipid storage disorders: Implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358 905-914 (2003).
3  Overkleeft, H.S., Renkema, G.H., Neele, J., et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem 273(41) 26522-26527 (1998).
4  Shen, C., Bullens, D., Kasran, A., et al. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. Int Immunopharmacol 4 939-951 (2004).
5  Aerts, J.M., Ottenhoff, R., Powlson, A.S., et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56 1341-1349 (2007).

Download Product Insert 141 Kb PDF
Download Material Safety Data Sheet (MSDS) 18 Kb PDF

Pricing Information

Prices listed here are the Manufacturer's Suggested European Retail Price. The actual prices quoted by each individual distributor may vary. Please visit the Global Buyer's Guide on the Cayman Chemical (world) website to locate a distributor in your region.

This product is also available to buy in bulk quantities. Please contact us for a quote or to purchase.

Cayman strives to be a reliable biochemical reagent vendor by providing the best possible products and services. To ask for assistance with one of our products please contact our Technical Help staff.

Warning This product is not for human or veterinary use.

Item total €0.00
Shopping cart total €0.00
Size Price Quantity
500 µg €40.00
1 mg €76.00
5 mg €317.00
10 mg €555.00
Pricing updated 2010-08-01.
Prices are subject to change without notice.